Laurus Labs Limited vs Venus Remedies Limited

A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Venus Remedies Limited (VENUSREM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Venus Remedies Limited leads LAURUSLABS vs VENUSREM on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation04
  • Profitability22
  • Growth02
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

VENUSREM takes 4/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

125.08
P/E ratio
20.51
19.74
P/B ratio
3.28
0.10%
Dividend yield
0.62%
₹16.47
EPS
₹76.90

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

16.77%
Return on equity
0.00%
17.58%
Return on capital
20.18%
26.09%
EBITDA margin
19.14%
13.07%
Net margin
13.36%

Growth

VENUSREM takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y)
11.71%
3.91%
Profit CAGR (3Y)
56.14%

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹2,195 Cr
₹6,813 Cr
Revenue
₹770 Cr
₹890 Cr
Net profit
₹103 Cr
0.45
Debt / equity
0.00
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
Venus Remedies Limited
  • + ["Company is almost debt free."]
  • − ["The company has delivered a poor sales growth of 7.2% over past five years."]
Laurus Labs Limited full analysis Venus Remedies Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.